All patients
age >= 55 yr age >= 60 yr age >= 65 yr delta variant (B.1.617.2, Indian) elderly (typically over 65yr) immunodepression omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC
first booster dose in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Arbel, 2021 0.10 [0.07; 0.14]
Barda, 2021 0.19 [0.05; 0.70]
McConeghy, 2022 0.03 [0.01; 0.10]
0.09 [0.04 ; 0.19 ] Arbel, 2021, Barda, 2021, McConeghy, 2022 3 55% 843,208 moderate not evaluable hospitalization or deathdetailed results Abu-Raddad, 2022 0.23 [0.12; 0.44]
McConeghy, 2022 0.54 [0.23; 1.26]
0.34 [0.15 ; 0.77 ] Abu-Raddad, 2022, McConeghy, 2022 2 59% NA not evaluable confirmed COVID (any severity)detailed results Abu-Raddad, 2022 0.51 [0.49; 0.54]
Accorsi, 2022 0.35 [0.33; 0.38]
Bar-On, 2021 0.09 [0.08; 0.10]
C4591031- first boost, 2021 0.05 [0.02; 0.13]
COVI3, 2022 0.07 [0.02; 0.22]
Kislaya, 2022 0.31 [0.18; 0.54]
Mattiuzzi, 2022 0.35 [0.32; 0.38]
McConeghy, 2022 0.49 [0.34; 0.70]
Patalon, 2021 0.21 [0.16; 0.28]
Patalon, 2022 0.15 [0.14; 0.17]
Tan, 2022 0.27 [0.26; 0.29]
0.23 [0.16 ; 0.32 ] Abu-Raddad, 2022, Accorsi, 2022, Bar-On, 2021, C4591031- first boost, 2021, COVI3, 2022, Kislaya, 2022, Mattiuzzi, 2022, McConeghy, 2022, Patalon, 2021, Patalon, 2022, Tan, 2022 11 99% 10,125 NA low hospitalizationdetailed results Barda, 2021 0.07 [0.04; 0.14]
Lauring, 2022 0.06 [0.05; 0.08]
Mattiuzzi, 2022 0.31 [0.22; 0.44]
McConeghy, 2022 0.52 [0.08; 3.59]
Patalon, 2022 0.08 [0.05; 0.13]
Tan, 2022 0.05 [0.03; 0.08]
Tenforde, 2022 0.18 [0.09; 0.35]
0.11 [0.06 ; 0.21 ] Barda, 2021, Lauring, 2022, Mattiuzzi, 2022, McConeghy, 2022, Patalon, 2022, Tan, 2022, Tenforde, 2022 7 92% 398,920 NA not evaluable symptomatic Covid-19detailed results Abu-Raddad, 2022 0.53 [0.47; 0.59]
Accorsi, 2022 0.35 [0.33; 0.38]
COVI3, 2022 0.07 [0.02; 0.25]
0.37 [0.24 ; 0.56 ] Abu-Raddad, 2022, Accorsi, 2022, COVI3, 2022 3 95% NA not evaluable ICU admissiondetailed results Mattiuzzi, 2022 0.33 [0.08; 1.36]
0.33 [0.08 ; 1.36 ] Mattiuzzi, 2022 1 0% NA not evaluable severe COVID-19 (FDA definition)detailed results C4591031- first boost, 2021 0.25 [0.01; 5.50]
0.25 [0.01 ; 5.50 ] C4591031- first boost, 2021 1 0% 10,125 NA not evaluable severe COVID-19 occurrencedetailed results Bar-On, 2021 0.06 [0.04; 0.10]
Barda, 2021 0.08 [0.03; 0.20]
C4591031- first boost, 2021 0.25 [0.01; 5.50]
Tan, 2022 0.05 [0.03; 0.08]
0.06 [0.05 ; 0.08 ] Bar-On, 2021, Barda, 2021, C4591031- first boost, 2021, Tan, 2022 4 0% 10,125 NA not evaluable arrhythmiadetailed results C4591031- first boost, 2021 1.99 [0.07; 59.22]
1.99 [0.07 ; 59.22 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable hypertensiondetailed results C4591031- first boost, 2021 0.50 [0.02; 14.80]
0.50 [0.02 ; 14.80 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable Myocardial infarction detailed results C4591031- first boost, 2021 0.74 [0.17; 3.33]
0.74 [0.17 ; 3.33 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable pulmonary embolismdetailed results C4591031- first boost, 2021 0.17 [0.01; 3.30]
0.17 [0.01 ; 3.30 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable stroke (non-specific, hemorrhagic, and ischemic)detailed results C4591031- first boost, 2021 0.99 [0.06; 15.88]
0.99 [0.06 ; 15.88 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable cerebral venous sinus thrombosis (CVST)detailed results C4591031- first boost, 2021 0.50 [0.02; 14.80]
0.50 [0.02 ; 14.80 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable appendicitisdetailed results C4591031- first boost, 2021 3.97 [0.18; 88.14]
3.97 [0.18 ; 88.14 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-28 13:20 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 89
- treatments: 1088,1331,1330,1329,1344,1328,1327
- roots T: 290